{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:43:08Z","timestamp":1761514988300,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"am","delay-in-days":305,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jpba.2023.115316","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T22:30:19Z","timestamp":1677277819000},"page":"115316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["LC-MS\/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing\u2019s Syndrome"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0359-0320","authenticated-orcid":false,"given":"David","family":"Balakirouchenane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axelle","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fid\u00e9line","family":"Bonnet-Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minna","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihel","family":"Khoudour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicja","family":"Puszkiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Groussin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Decl\u00e8ves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115316_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"389","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2023.115316_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jpba.2023.115316_bib3","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing\u2019s Syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jpba.2023.115316_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jpba.2023.115316_bib5","doi-asserted-by":"crossref","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","article-title":"Metyrapone treatment in endogenous Cushing\u2019s Syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study","volume":"5","author":"Nieman","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.jpba.2023.115316_bib6","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s Disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jpba.2023.115316_bib7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jpba.2023.115316_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","article-title":"Cushing\u2019s disease: adrenal steroidogenesis inhibitors","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"unstructured":"FDA Label, METOPIRONE (Metyrapone capsules) (1961). \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/012911s038lbl.pdf\u3009 Accessed October 10, 2022).","key":"10.1016\/j.jpba.2023.115316_bib9"},{"key":"10.1016\/j.jpba.2023.115316_bib10","first-page":"908","article-title":"Some aspects of the pharmacology of metyrapone","volume":"60","author":"Sprunt","year":"1967","journal-title":"Proc. R. Soc. Med"},{"unstructured":"FDA Label, ISTURISA (Osilodrostat tablets) (2020). \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212801s000lbl.pdf\u3009 (Accessed October 10, 2022).","key":"10.1016\/j.jpba.2023.115316_bib11"},{"unstructured":"EMA Assessment report, ISTURISA (Osilodrostat tablets) (2019). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/isturisa-epar-public-assessment-report_.pdf\u3009 (Accessed October 10, 2022).","key":"10.1016\/j.jpba.2023.115316_bib12"},{"key":"10.1016\/j.jpba.2023.115316_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-22-0208","article-title":"Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients","volume":"187","author":"Bonnet-Serrano","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.jpba.2023.115316_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.jpba.2023.115316_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jpba.2023.115316_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.trac.2016.03.019","article-title":"The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine","volume":"84","author":"Decosterd","year":"2016","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.jpba.2023.115316_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/jcem-40-2-290","article-title":"Single dose metyrapone test: 11\u03b2-Hydroxylase inhibition by metyrapone and reduced metyrapone assayed by radioimmunoassay","volume":"40","author":"Meikle","year":"1975","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jpba.2023.115316_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-4347(94)00500-5","article-title":"Determination of metyrapone and the enantiomers of its chiral metabolite metyrapol in human plasma and urine using coupled achiral-chiral liquid chromatography","volume":"665","author":"Chiarotto","year":"1995","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jpba.2023.115316_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1248\/bpb.20.188","article-title":"Stereoselective reductive metabolism of metyrapone and inhibitory activity of metyrapone metabolites, metyrapol enantiomers, on steroid 11 beta-hydroxylase in the rat","volume":"20","author":"Nagamine","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpba.2023.115316_bib20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/chir.10133","article-title":"Determination of the plasma levels of metyrapone and its enantiomeric metyrapol metabolites by direct plasma injection and multidimensional achiral-chiral chromatography","volume":"14","author":"Cassiano","year":"2002","journal-title":"Chirality"},{"key":"10.1016\/j.jpba.2023.115316_bib21","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jchromb.2014.04.012","article-title":"A semi-automated LC\u2013MS\/MS method for the determination of LCI699, a steroid 11\u03b2-hydroxylase inhibitor, in human plasma","volume":"960","author":"Li","year":"2014","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115316_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijms.2017.12.006","article-title":"Enhancing sensitivity of liquid chromatography\u2013mass spectrometry of peptides and proteins using supercharging agents","volume":"427","author":"Nshanian","year":"2018","journal-title":"Int. J. Mass Spectrom."},{"unstructured":"FDA, Bioanalytical Method Validation - Guidance for Industry (2018). \u3008https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf\u3009 (Accessed January 04, 2023).","key":"10.1016\/j.jpba.2023.115316_bib23"},{"unstructured":"EMA, Guideline on bioanalytical method validation (2011). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf\u3009 (Accessed January 04, 2023).","key":"10.1016\/j.jpba.2023.115316_bib24"},{"key":"10.1016\/j.jpba.2023.115316_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00216-011-5308-5","article-title":"Hydrophilic interaction liquid chromatography (HILIC)\u2014a powerful separation technique","volume":"402","author":"Buszewski","year":"2012","journal-title":"Anal. Bioanal. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:27:22Z","timestamp":1760002042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":25,"alternative-id":["S0731708523000857"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115316","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC-MS\/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing\u2019s Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115316"}}